Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • Daniel Fernandez
    Member
    • Nov 2011
    • 31

    Glimmer: Multifasta analysis

    Hi everyone.
    I am new user at glimmer. We have a bacterial genome in multifasta, contigs. We can predict the ORF, if we could a complete genome in one fasta, we could, but we with Multifasta, we can make a a lot of things and I'm pretty sure that we're wrong.

    First, we separate the Genome.fas in 128 fasta files (beacuse it has 128 sequences), for make a *.train file we create a lot of *.train for any contig and put them all together in one file run.train

    Code:
    long-orfs -n -t 1.15 Contig1 run1.longorfs && extract -t Contig1 run1.longorfs > run.train
    ...
    long-orfs -n -t 1.15 Contig128 run128.longorfs && extract -t Contig128 run128.longorfs >> run.train
    then we create a *.icm model

    Code:
    build-icm -r model.icm < run.train
    but I compared it with other analysis of my friend, for he, all *logorfs are the same name, so he replace in any line this file. But my friend and my, we can the SAME NUMBER OF ORF!!!.

    Code:
    long-orfs -n -t 1.15 Contig1 [B]run1.longorfs[/B] && extract -t Contig1 [B]run1.longorfs[/B] > run.train
    ...
    long-orfs -n -t 1.15 Contig128 [B]run1.longorfs[/B] && extract -t Contig128 [B]run1.longorfs[/B] >> run.train
    Code:
    build-icm -r model.icm < run.train
    So, my friend and my, we can the SAME NUMBER OF ORF!!! although we did diferent things. I'm pretty sure that we're wrong.

    So. How do you analyse MultiFasta with Glimmer?
    And how do yu extract the fasta from *.predict file in mulifasta?

    Please, healp.

Latest Articles

Collapse

  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM
  • SEQadmin2
    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
    by SEQadmin2



    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
    07-08-2026, 05:17 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 07-24-2026, 12:17 PM
0 responses
26 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-23-2026, 11:41 AM
0 responses
21 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-20-2026, 11:10 AM
0 responses
210 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-13-2026, 10:26 AM
0 responses
78 views
0 reactions
Last Post SEQadmin2  
Working...